baber/WOPTO huggingface dataset:
Patent CA-3053827-A1 (CA)
Title: Fallback prevention valve apparatus, system and method
Inventor: NOWITZKI WESLEY JOHN
IPC: F04D15/00
Filed: 2018-05-22
Abstract: A fallback prevention valve apparatus, system and method is described. An electric submersible pump (ESP) fallback prevention system includes an ESP assembly positioned in a downhole well, the ESP assembly including production tubing extending between a centrifugal pump and a surface of the downhole well such that during operation of the ESP assembly production fluid flows upward from the centrifugal pump through the production tubing to the surface, the production tubing including a fallback valve actuatable by the flow of production fluid, the fallback valve actuatable between an open position, wherein production fluid flowing upward through the fallback valve actuates the fallback valve into the open position, and a closed position, wherein production fluid flowing downward through the fallback valve actuates the fallback valve into the closed position, the closed position blocking sand carried by the production fluid from falling into the centrifugal pump.
Patent CA-3054662-A1 (CA)
Inventor: ANDREWS DAVID W
IPC: C07H21/04
Filed: 2018-03-09
Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-IR). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
Patent CA-3056400-A1 (CA)
Inventor: LINDSKOG KJELL
IPC: H05B3/28
Filed: 2018-02-02
Abstract: L'invention concerne un procédé d'application de nappe chauffante (10) sur une aile/pale dans un parc éolien ou d'autres dispositifs dans le but de réaliser également un dégivrage en cas de besoin pendant le fonctionnement. La mesure de température et le dégivrage ont lieu au moyen d'un courant pulsé vers la nappe chauffante (10). L'invention porte également sur un agencement.
Patent CA-3056480-A1 (CA)
Inventor: GROSS DIETMAR
IPC: B65B9/22
Filed: 2018-03-13
Abstract: The invention relates to a device for packaging pharmaceutical portions. In known devices, the packaging or blister-packing process of the pharmaceutical portions is prone to error. In order to solve this problem, the invention provides a device which has a plurality of storage and dispensing stations (10); at least one guide and collecting assembly; a packaging material supply (40); a packaging device (30) with a folding and guiding device (50), said folding and guiding device (50) having a packaging material receiving region (52) with a through-opening (51); a guide device (60) which is arranged above the folding and guiding device (50) and which comprises a receiving section (61) for pharmaceutical portions and a guide section (62) that extends in the direction of the through-opening (51) of the folding and guiding device (50); a first joining device (70) which is arranged downstream of the folding and guiding device (50); and a second joining device (90) which is arranged downstream of the first joining device (70).
Patent CA-3056809-A1 (CA)
Title: Method for determining closed-control parameters for a hydraulic system
Inventor: ZEHETLEITNER KURT
IPC: G05B13/04
Filed: 2018-03-20
Abstract: In order to carry out largely automated parameterisation of the closed-loop control parameters for closed-loop control of a hydraulic system comprising a servo drive, a method and a device for determining the closed-loop parameters of a closed-loop control unit of the hydraulic system are specified, wherein an actual system pressure of a hydraulic consumer of the hydraulic system is closed-loop controlled by means of a predefined set point rotational speed of a servo drive, wherein an actual rotational speed of the servo drive follows the predefined set point rotational speed, wherein an excitation signal is applied to the setpoint rotational speed, and the actual system pressure which is set here is measured, the dynamics of the hydraulic system are acquired from the actual rotational speed and/or the setpoint rotational speed and the actual system pressure, and the closed-loop control parameters are calculated from the acquired dynamics.
Patent CA-3057200-A1 (CA)
Inventor: NGUYEN DUY D
IPC: F16L27/00
Filed: 2019-10-01
Abstract: Swivel joints comprise a male sub, a female sub, annular races, ball bearings, a replaceable sleeve, and first and second pressure seals. The male sub is rotationally coupled to the female sub at, respective, generally tubular joint ends thereof. A passage extends through the subs. The female joint end and male joint end are rotationally coupled by ball bearings in the annular races. The replaceable sleeve is received in enlarged inner diameter portions of the male joint end and the female joint end. The first pressure seal ring is mounted between the replaceable sleeve and the enlarged diameter portion of the male joint end. The second pressure seal ring is mounted between the replaceable sleeve and the enlarged diameter portion of the female joint end.
Patent CA-3061910-A1 (CA)
Inventor: SAID NUDER
IPC: F16K17/16
Filed: 2018-04-30
Abstract: L'invention concerne un ensemble soupape de sécurité comprenant un disque de rupture qui est formé de façon à ne pouvoir être inséré dans une cavité de disque de rupture particulière que de la manière correcte. Le disque de rupture comprend une tige de disque de rupture cylindrique et une lèvre supérieure faisant saillie radialement. Un corps de soupape de décharge dans l'ensemble d'évacuation de pression comprend un épaulement radial interne à l'entrée du disque de rupture qui est plus étroit que la lèvre supérieure faisant saillie du disque de rupture mais qui est plus large que la tige de disque de rupture. L'épaulement permet d'insérer uniquement la tige de disque de rupture dans la cavité de disque de rupture, pas la lèvre supérieure faisant saillie. Facultativement, le corps de soupape de décharge est marqué avec certains indices pour indiquer la direction d'insertion de la tige de disque de rupture et/ou d'un dispositif de capture d'éclats destiné à piéger les éclats du disque de rupture lors de la rupture.
Patent CA-3062420-A1 (CA)
Inventor: PAMEL GREGORY J
IPC: A61K33/00
Filed: 2018-05-07
Abstract: The present invention relates to a composition comprising chlorine dioxide useful in the treatment of active infections of the eye, as well as prophylaxis and treatment of such infections. The invention also relates to uses of compositions including effective amounts of chlorine dioxide in the eye to obtain benefit without detrimentally affecting the eye.
Patent CA-3063043-A1 (CA)
Title: Neonate medical wraps for a baby and parent, and related methods
Inventor: CHIESA MARY
IPC: A45F3/14
Filed: 2018-07-10
Abstract: Disclosed is a neonate medical wrap. In one embodiment, the neonate medical wrap is a wrap-style baby carrier that is particularly useful during the first 28 days after the baby's birth. Generally, the disclosed neonate medical wrap comprises a torso wrap and a shoulder strap. In use, the torso wrap and shoulder strap may be outfitted around the torso of a parent and, via a side opening, a baby may be installed against the parent's skin under the torso wrap. The shoulder strap may be provided over the shoulder of the parent to assist in supporting the baby's weight while standing.
Patent CA-3068836-A1 (CA)
Title: Compounds and compositions for treating conditions associated with nlrp activity
Inventor: GLICK GARY
IPC: C07D231/18
Filed: 2018-07-23
Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
Patent CA-3068923-A1 (CA)
Title: Calibration fluid comprising pyrogallol for the calibration of blood gas, electrolyte, and/or metabolite instrument oxygen sensor(s)
Inventor: HORAN KEVIN
IPC: A61B5/1495
Filed: 2018-07-02
Abstract: Compositions, devices, kits, and methods for calibrating at least one oxygen sensor in a blood gas, electrolyte, and/or metabolite instrument utilizing a calibration fluid comprising a pyrogallol oxygen scavenger.
Patent CA-3069457-A1 (CA)
Inventor: WAZIRI ALLEN
IPC: A61M27/00
Filed: 2018-07-16
Abstract: La présente invention concerne des systèmes et des procédés de positionnement d'un dispositif intracrânien. Certains modes de réalisation de l'invention englobent des dispositifs configurés pour une implantation dans le corps qui comprennent des éléments responsables de la détection et de la transmission d'une activité électrique à partir des tissus et fluides environnants. Le système peut comprendre un matériel et un logiciel associés conçus pour transmettre, traiter, analyser et afficher des aspects pertinents de l'activité électrique détectée. Ces informations peuvent être utilisées pendant ou après une procédure d'insertion pour optimiser ou confirmer la position du dispositif à l'intérieur d'un emplacement intracrânien particulier ou d'un compartiment tissulaire particulier.
Patent CA-3071309-A1 (CA)
Inventor: PERACHA MAX
IPC: C07K14/245
Filed: 2018-08-01
Abstract: Human milk oligosaccharides (HMOs) may be used e.g. as functional ingredients in infant nutrition, medical nutrition, functional foods and animal feed. There is still a need of improved means of producing HMOs. The present invention provides genetically modified microorganisms for the improved production of HMOs and HMO production methods using the same. The microorganisms of the invention may have one or more yield-enhancing modifications, including an inducible lysis system, which allows for the easy extraction of intracellular and extracellular HMOs, lactose pennease mutants, which may increase intracellular lactose levels, or chaperones, which may increase intracellular availability of key enzymes for the production of HMOs.
Patent CA-3077960-A1 (CA)
Title: N- [(2'r) -2'-deoxy-2'-fluoro-2' -methyl-p-phenyl-5' -uridylyl] -l-alanine 1-methylethyl ester and process for its production
Inventor: ROSS BRUCE S
IPC: C07H19/073
Filed: 2010-05-20
Abstract: Disclosed herein are processes for preparing a compound represented by formula 4 and which comprises: a) reacting an isopropyl-alanate, A, a di-X'-phenylphosphate, B, 2'-deoxy-2'-fluoro-2'-C-methyluridine, 3, and a base to obtain a first mixture comprising 4, or the phosphorous-based diastereomer thereof; b) reacting the first mixture with a protecting compound to obtain a second mixture comprising 4, or the phosphorous-based diastereomer thereof, and a protected side product, wherein the protecting compound is t-butyl-dimethyl-silyl-chloride; and c) subjecting the second mixture to crystallization, chromatography, or extraction in order to obtain 4, or the phosphorous-based diastereomer thereof.
Patent CA-3078270-A1 (CA)
Inventor: FRAIETTA JOSEPH A
IPC: C12N5/0783
Filed: 2018-10-25
Abstract: The disclosure provides methods of making CAR-expressing immune effector cells (e.g., T cells, or NK cells), and compositions and reaction mixtures comprising the same. The disclosure further provides methods of using said CAR-expressing immune effector cells.
Patent CA-3079301-A1 (CA)
Title: A method for manufacturing coated titanium dioxide particles, coated titanium dioxide particles and products comprising thereof
Inventor: LAMMINMAKI RALF-JOHAN
IPC: C09D7/61
Filed: 2018-10-15
Abstract: The present disclosure provides a method for manufacturing pigmentary titanium dioxide particles coated with SiO2 coating layer. The method comprises the steps of (i) forming an aqueous dispersion containing rutile titanium dioxide particles having an average particle size of in the range of 71000 nm, (ii) introducing to said dispersion of step (i) a silicon containing compound and a base, (iii) adding to the dispersion obtained from step ii acid, (iv) repeating the steps ii and iii at least once. Finally, the pH of the dispersion is lowered to a value within the range from 1.9 to 9.0 before filtering and washing thus obtained product.
Patent CA-3079926-A1 (CA)
Inventor: LINDSTROM HENRIK
IPC: H01G9/20
Filed: 2018-11-30
Abstract: The present invention relates to a solar cell and a method of producing the same. The solar cell comprises a porous light absorbing layer(1),a first porous conducting layer (2), a second conducting layer (3),a porous substrate (4) between the conducting layers, the porous substrate comprises a catalytic conducting portion (4a) in electrical contact with the second conducting layer and an insulating portion (4b) between the first porous conducting layer (2) and the conducting portion, and a conducting medium (5) for transporting charges between the conducting portion (4a) and the light absorbing layer (1). The conducting medium is locatedin the light absorbing layer (1), the first porous conducting layer(2), and partly the porous substrate (4) so that the insulating portion (4b) and a first part (4a') of the conducting portion (4a) comprises the conducting medium and a second part (4a'') of the conducting portion is free of conducting medium.
Patent CA-3082504-A1 (CA)
Title: Access rejection method, apparatus and system, and storage medium and processor
Inventor: XIE ZHENHUA
IPC: H04W12/08
Filed: 2018-08-10
Abstract: Disclosed are an access rejection method, apparatus and system, where the access rejection method includes: a first base station receives an access request from a terminal; and the first base station sends an access rejection message to the terminal; where the access rejection message at least carries: a check value generated based on a key of the terminal and at least part of contents of the access rejection message. And further disclosed are related computer storage media and processors.
Patent CA-3085751-A1 (CA)
Title: Anticorps fcrn et leurs procedes d'utilisation
Inventor: HILLSON JAN
IPC: A61K39/395
Filed: 2018-12-13
Abstract: La présente invention concerne des anticorps qui se lient au récepteur Fc néonatal humain (FcRn). Ces anticorps anti-FcRn sont utiles, par exemple, pour favoriser la clairance d'auto-anticorps chez un sujet, pour supprimer la présentation de l'antigène chez un sujet, pour bloquer une réponse immunitaire, par exemple pour bloquer une activation, basée sur des complexes immuns, de la réponse immunitaire chez un sujet, et pour traiter des maladies immunologiques (par exemple des maladies auto-immunes) chez un sujet. Ces anticorps anti-FcRn sont également utiles, par exemple, pour réduire le transport d'anticorps pathogènes à travers le placenta d'une femme enceinte, pour augmenter le catabolisme d'anticorps pathogènes chez une femme enceinte, et pour traiter une amélioration, médiée par anticorps, d'une maladie virale chez un ftus ou un nouveau-né.
Patent CA-3086272-A1 (CA)
Inventor: TJERNBERG FREDRIK
IPC: B60W50/02
Filed: 2018-12-12
Abstract: L'invention concerne un engin de chantier et un procédé de surveillance d'un système de commande au niveau d'un engin de chantier (1a). Selon le procédé, des paramètres d'entrée (32, 34, 36, 38) sont obtenus sous la forme de signaux provenant du système de commande, le système de commande produisant des valeurs réelles sur un ou plusieurs paramètres de sortie (42, 44) sous la forme de signaux basés sur lesdits paramètres d'entrée. Une caractéristique de l'invention est qu'un flux numérique de données, comprenant à la fois lesdits paramètres d'entrée et paramètres de sortie par l'intermédiaire d'un bus de commande (5a, 5b), est adressé à une mémoire tampon RAM (3b,3c), qui est présente dans un ordinateur personnel (3a) à bord de l'engin de chantier, laquelle mémoire tampon en mode FIFO écrit un fichier de données (id:1 - id:1:n) d'une taille prédéterminée, qui est sauvegardé dans une mémoire de support de données non volatile (3d).
Patent CA-3086712-A1 (CA)
Title: Unitary laundry detergent article
Inventor: TAN HONGSING
IPC: C11D17/00
Filed: 2018-01-26
Abstract: A water-soluble unitary laundry detergent article that contains two or more surfactant-containing non-fibrous sheets with a fabric hueing agent located between such non-fibrous sheets.
Patent CA-3086718-A1 (CA)
Title: Composition for treating a patient with a respiratory disease caused by chronic inflammation, production method, and use of said composition
Inventor: RENZ JONAS
IPC: A61P11/06
Filed: 2018-12-20
Abstract: The invention relates to a composition for treating a patient with a respiratory disease caused by chronic inflammation, said composition comprising at least one DNAzyme that specifically down-regulates the expression of GATA-3 and/or at least one DNAzyme that specifically down-regulates the expression of Tbet. The composition is characterised in that the concentration of the DNAzyme in the composition is lower than 75 mg/ml. The invention also relates to a method for producing the composition according to the invention, and to a use of the composition as a medicament for treating a patient with a respiratory disease caused by chronic inflammation.
Patent CA-3088198-A1 (CA)
Inventor: BANNEN LYNNE CANNE
IPC: C07D471/04
Filed: 2019-01-25
Abstract: Disclosed herein are compounds of Formula I'. Compounds of Formula I' inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase- dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Patent CA-3090035-A1 (CA)
Inventor: KJELLIN PER
IPC: A61L27/54
Filed: 2019-02-08
Abstract: This invention is directed to coated substrates, wherein the coating comprises titanium phosphate and/or zirconium phosphate. In certain embodiments the substrate is an implant for use in vivo. The invention is also directed to methods for forming coatings comprising or consisting of titanium phosphate and/or zirconium phosphate on the surface of a substrate.
Patent CA-3091814-A1 (CA)
Title: Dyes for analysis of soluble protein aggregates or misfolded protein oligomers
Inventor: ZHANG XIN
IPC: C07D233/70
Filed: 2019-03-07
Abstract: Dye and compositions to monitor the multistep protein aggregation process in both test tubes and live cells are provided. These dyes can detect misfolded protein oligomers and distinguish insoluble protein aggregates from misfolded oligomers. Applications of these dyes include measuring kinetics of protein aggregation, monitoring aggregation of specific proteins in intact live cells, monitoring aggregation of cellular proteome in intact live cells, and tracking the time course of protein aggregation in cells under stress conditions.
Patent CA-3093915-A1 (CA)
Inventor: BENSON MICAH
IPC: C12N15/63
Filed: 2019-03-14
Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
Patent CA-3094165-A1 (CA)
Title: Beverage container open indicator
Inventor: DELGADO CARMONA SARA L
IPC: A45F3/18
Filed: 2020-09-24
Abstract: Atty Docket No. 132081-M200 ABSTRACT OF THE DISCLOSURE A beverage container with a tactile indication of a properly open position for drinking. The beverage container includes a base, a collar, and a cap having an annular seal gasket for opening and closing the container for pouring/drinking. The improvement is a collar stop located on the collar, together with a pair of seal stops extending from the seal gasket and forming a notch therebetween. Rotation of the cap to open the container becomes more difficult as the collar stop interferes with the leading one of the seal stops.  Continued rotation to seat the collar stop in the notch provides a tactile indication that the cap has rotated to the properly open position and further rotation may be avoided.   Date Recue/Date Received 2020-09-24
Patent CA-3094372-A1 (CA)
Inventor: TROMBETTA LIBERATORE
IPC: A23P10/40
Filed: 2019-04-23
Abstract: Une capsule ou un contenant présentant des attributs de recyclage optimisés est décrit. La capsule est destinée à être utilisée dans une machine pour préparer un produit consommable à partir de capsules. La capsule comprend un corps qui délimite un espace intérieur comportant une ouverture. Un couvercle est disposé sur louverture. Un filtre est disposé dans lespace intérieur pour délimiter une chambre entre le filtre et le couvercle. Le corps, le filtre et le couvercle sont de préférence constitués du même matériau polymère sensiblement pur. Des ingrédients sont disposés dans lespace intérieur pour préparer un produit souhaité. Une charnière est prévue pour attacher le couvercle au corps. Le couvercle est fixé avec un joint pelable au corps de sorte que le couvercle peut être détaché du corps tout en restant attaché au niveau de la charnière.
Patent CA-3095804-A1 (CA)
Inventor: WEINFELD DORON
IPC: A61F2/24
Filed: 2019-04-01
Abstract: A system and method for treating a patient may include implanting an apparatus that includes a tube housing a one-way valve and having first and second surfaces. When the apparatus is implanted, the first surface is located inside the right atrium of the patient and the second surface is located on the skin of the patient. When implanted, the apparatus is used for drawing blood from the right atrium and/or providing a liquid to the patient. The apparatus may be designed to be hermetically sealed when disconnected from input and output lines.
Patent CA-3097783-A1 (CA)
Inventor: SMITH HOUSTON
IPC: A23K20/00
Filed: 2020-02-21
Abstract: A taste mask composition for ketone bodies, ketone body salts, ketone body esters, ketone body amides, or mixtures thereof comprising (a) at least one of the foregoing in combination with (b) propylene glycol, (c) ethanol, (d) water, (e) natural or synthetic flavors selected from bitter orange or grape or mixtures thereof, (f) a high potency sweetener, and a synthetic bitter mask agent.
Patent CA-3101058-A1 (CA)
Inventor: HANLON THOMAS
IPC: A61K9/14
Filed: 2019-06-19
Abstract: This disclosure provides a dry powder formulation of free amino acids with an acceptable and even good taste profile.